MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41541-023-00630-0

Медицинская библиотека · NPJ vaccines · 2023

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine.

Benkeser David, Fong Youyi, Janes Holly E, Kelly Elizabeth J, Hirsch Ian, Sproule Stephanie, Stanley Ann Marie, Maaske Jill, Villafana Tonya, Houchens Christopher R, Martins Karen, Jayashankar Lakshmi, Castellino Flora, Ayala Victor, Petropoulos Christos J, Leith Andrew, Haugaard Deanne, Webb Bill, Lu Yiwen, Yu Chenchen, Borate Bhavesh, van der Laan Lars W P, Hejazi Nima S, Carpp Lindsay N, Randhawa April K, Andrasik Michele P, Kublin James G, Isaacs Margaret Brewinski, Makhene Mamodikoe, Tong Tina, Robb Merlin L, Corey Lawrence, Neuzil Kathleen M, Follmann Dean, Hoffman Corey, Falsey Ann R, Sobieszczyk Magdalena, Koup Richard A, Donis Ruben O, Gilbert Peter B, AstraZeneca AZD1222 Clinical Study Group, Immune Assays Team, United States Government (USG)/CoVPN Biostatistics Team

СтатьяПеревод в очереди

Аннотация

In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the U.S., Chile, and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured four weeks after two doses were assessed as correlates of risk and protection against PCR-confirmed symptomatic SARS-CoV-2 infection (COVID-19). These analyses of SARS-CoV-2 negative participants were based on case-cohort sampling of vaccine recipients (33 COVID-19 cases by 4 months post dose two, 463 non-cases). The adjusted hazard ratio of COVID-19 was 0.32 (95% CI: 0.14, 0.76) per 10-fold increase in spike IgG concentration and 0.28 (0.10, 0.77) per 10-fold increase in nAb ID50 titer. At nAb ID50 below the limit of detection (< 2.612 IU50/ml), 10, 100, and 270 IU50/ml, vaccine efficacy was -5.8% (-651%, 75.6%), 64.9% (56.4%, 86.9%), 90.0% (55.8%, 97.6%) and 94.2% (69.4%, 99.1%). These findings provide further evidence towards defining an immune marker correlate of protection to help guide regulatory/approval decisions for COVID-19 vaccines.

Для цитирования: Benkeser David, Fong Youyi, Janes Holly E, Kelly Elizabeth J, Hirsch Ian, Sproule Stephanie, Stanley Ann Marie, Maaske Jill, Villafana Tonya, Houchens Christopher R, Martins Karen, Jayashankar Lakshmi, Castellino Flora, Ayala Victor, Petropoulos Christos J, Leith Andrew, Haugaard Deanne, Webb Bill, Lu Yiwen, Yu Chenchen, Borate Bhavesh, van der Laan Lars W P, Hejazi Nima S, Carpp Lindsay N, Randhawa April K, Andrasik Michele P, Kublin James G, Isaacs Margaret Brewinski, Makhene Mamodikoe, Tong Tina, Robb Merlin L, Corey Lawrence, Neuzil Kathleen M, Follmann Dean, Hoffman Corey, Falsey Ann R, Sobieszczyk Magdalena, Koup Richard A, Donis Ruben O, Gilbert Peter B, AstraZeneca AZD1222 Clinical Study Group, Immune Assays Team, United States Government (USG)/CoVPN Biostatistics Team. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine.. NPJ vaccines. 2023. DOI: 10.1038/s41541-023-00630-0.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.